644 Gastric Peroral Endoscopic Myotomy (G-Poem) for the Treatment of Refractory Gastroparesis: Results From the First International Prospective Trial

Vosoughi, Kia; Ichkhanian, Yervant; Benias, Petros C.; Miller, Larry S.; Aadam, A. Aziz; Triggs, Joseph; Law, Ryan; Chaves, Dalton Marques; Ponte, Alberto M. da; Draganov, Peter V.; Kotzev, Andrey; Halabi, Maan El; Gutierrez, Olaya I. Brewer; Pandolfino, John E.; Kalloo, Anthony N.; Khashab, Mouen A.

doi:10.1016/j.gie.2019.04.098

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 75 % of our patients had a symptomatic response to POP, consistent with reported clinical improvement rates of 56 %–87 % in studies comprising at least 10 patients 24 25 . Three recent meta-analyses also demonstrated an 82 %–83.9 % clinical symptomatic response with POP 14 15 16 .…”

Section: Discussionsupporting

confidence: 87%

“…Our response to POP was 64 % using a decrease in GCSI by ≥ 1, as recommended in the 2017 American Gastroenterological Association White Paper as a more specific threshold for improvement 17 . Similarly, a recent prospective multicenter trial 24 found a more modest success rate of 56 % when the outcome of GCSI decrease by at ≥ 1 point was assessed 12 months after POP.…”

Section: Discussionmentioning

confidence: 87%

“…Finally, the time at which symptomatic improvement for POP was evaluated was not sufficient for assessment of a long-term response; however, we collected the symptomatic response at 30 days or more, which has been used in previous studies 32 33 34 . Furthermore, a recent prospective study by Vosoughi et al evaluating the safety and efficacy of POP showed that response to POP at 1 month was an independent predictor of response to POP at 12 months 24 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Response to botulinum toxin may predict response to peroral pyloromyotomy in patients with gastroparesis

et al. 2022

View full text Add to dashboard Cite

Background and study aims: Gastroparesis patients that have undergone prior intrapyloric Botulinum toxin injection (BTI) may seek an opinion regarding peroral pyloromyotomy (POP). There are only two small reports assessing the role of BTI as a predictor for successful treatment with POP. Patients and methods: We performed a retrospective cohort study to assess whether symptomatic improvement after BTI predicts a response to POP. We included 119 patients who had undergone both BTI and POP at Cleveland Clinic Ohio or Cleveland Clinic Florida from January 2016 to September 2019. Results: 67% of patients had symptomatic improvement to BTI. Gastroparesis Cardinal Symptom Index (GCSI) scores were available in 74 patients with 64% achieving response as defined by a decrease in mean GCSI ≥1. In multivariable analysis, response to BTI (OR 7.7 [95% CI 2.24-26.1]) and higher pre-POP GCSI (OR 2.3 [95% CI 1.2-4.6]) were found to be independent predictors of POP response Conclusions: Clinical improvement after BTI is a predictor of response to POP in patients with gastroparesis. This information may aid in improving patient selection for POP.

show abstract